The combined administration of ACLY inhibitor and IGF1R inhibitor significantly disrupted the IGF1-HOXA13-IGF1R feedback loop and suppressed HOXA13-induced CRC metastasis. This evidence concerns the gene IGF1 and colorectal carcinoma.